Orchid Pharma Ltd (ORCHPHARMA) — shareholding pattern, promoter holding, financials and share price
About Orchid Pharma Ltd (ORCHPHARMA)
Orchid Pharma Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ORCHPHARMA and on the BSE under scrip code 524372. Its ISIN is INE191A01027.
Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. [1]
Orchid Pharma Limited is a vertically integrated pharmaceutical company focused on development, manufacture and global commercialisation of APIs and finished dosages, with particular strength in cephalosporin antibiotics, sterile injectables and an emerging branded/licensing platform led by its new Orchid Antimicrobial Solutions (AMS) division and recently acquired European assets.
Q3 FY26 financials show stress: standalone sales fell to INR207 crore (-5% YoY) and 9M sales to INR574 crore (-16% YoY), EBITDA margins compressed to 6% in Q3 from 17% a year ago, gross margin declined to 31% versus prior ~43%, and Q3 reported a small loss (PAT negative INR6 crore) driven by industry-wide antibiotic price erosion and inventory adjustments.
Listed peers in Pharmaceuticals: Innova Captab Ltd, Bliss GVS Pharma Ltd, IOL Chemicals & Pharmaceuticals Ltd, Zota Health Care Ltd, RPG Life Sciences Ltd, Unichem Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹1,007.85 a share on 10 Jul 2026, Orchid Pharma Ltd (ORCHPHARMA) was valued at a price-to-earnings ratio of 243.18x against an industry P/E of 36.41x and a price-to-book of 4.03x on a book value of ₹249.86 per share as of Mar 2025. Solomo computes return on equity of 1.66% and return on capital employed of 2.38% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 243.18x
- Industry P/E
- 36.41x
- P/B
- 4.03x
- EPS (TTM)
- ₹4.14
- Book value / share
- ₹249.86
- ROE
- 1.66%
- ROCE
- 2.38%
- ROA
- 1.25%
- Debt / equity
- 0.14x
- Dividend yield
- 0%
- EBITDA margin
- 8.59%
- 52-week range
- ₹471.3 – ₹1,096.4
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Orchid Pharma Ltd (ORCHPHARMA) reported revenue of ₹811 crore, net profit of ₹21 crore and earnings per share of ₹4.05. That compares with revenue of ₹922 crore and net profit of ₹100 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹238 crore and net profit ₹24 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 560 | 666 | 819 | 922 | 811 |
| Net profit (₹ cr) | -2 | 46 | 92 | 100 | 21 |
| EPS (₹) | -0.48 | 11.35 | 18.17 | 19.65 | 4.05 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 0.39% | 13.89% | 18.29% | 12.52% |
| Profit growth | - | - | - | 0.74% |
| Stock price CAGR | 39% | 15% | 25% | 44% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 69.84% of Orchid Pharma Ltd (ORCHPHARMA) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.81% and domestic institutional investors (DII) hold 20.75%. Market capitalisation was ₹5,112 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: QUANT MUTUAL FUND - QUANT SMALL CAP FUND 6.83%, KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK CONSUMPTION FUND AND 7 OTHERS 4.6%, UTI SMALL CAP FUND AND 3 OTHERS 3.46%, INVESCO INDIA CONTRA FUND AND 2 OTHERS 2.87%, BANDHAN SMALL CAP FUND AND 5 OTHERS 1.53%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 69.84% | - | 0.81% | 20.75% | 30.16% |
| Mar 2026 | 69.84% | - | 0.87% | 20.25% | 30.16% |
| Dec 2025 | 69.84% | - | 1.17% | 19.39% | 30.16% |
| Sep 2025 | 69.84% | - | 1.56% | 19.04% | 30.16% |
| Jun 2025 | 69.84% | - | 1.4% | 19.43% | 30.16% |
| Mar 2025 | 69.84% | - | 2.69% | 20.1% | 30.16% |
| Dec 2024 | 69.84% | - | 2.53% | 18.99% | 30.16% |
| Sep 2024 | 69.84% | - | 1.94% | 18.29% | 30.16% |